Ziprasidone in Bipolar Disorder With Comorbid Lifetime Panic or Generalized Anxiety Disorder(GAD)
Status:
Completed
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
The specific aim of this study is to evaluate the efficacy, tolerability, and safety of
ziprasidone monotherapy in comparison to placebo in the treatment of ambulatory bipolar
disorder with co-morbid lifetime panic disorder or generalized anxiety disorder and current
at least moderately severe anxiety.
Phase:
Phase 4
Details
Lead Sponsor:
VA Palo Alto Health Care System
Collaborators:
Lindner Center of HOPE Pfizer University of South Florida